Biden's Pick for HHS Secretary Faces Scrutiny, Pfizer CEO Weighs In
Robert F. Kennedy Jr.'s nomination for the role of Health and Human Services (HHS) secretary cleared a crucial Senate committee today. Speculation abounds as to its implications for the pharmaceutical industry, particularly vaccine manufacturers.
Pfizer CEO Albert Bourla, however, dismisses concerns. In an interview with Yahoo Finance, Bourla expressed confidence that Kennedy's views on vaccines are not as extreme as perceived.
Bourla revealed that during a meeting with Kennedy and former President Trump, Kennedy moderated his stance on vaccines. Bourla believes that Kennedy's actions will primarily target vaccine capabilities, sparking resistance from the medical community and insurance providers.
Despite his controversial history, including legal actions against pharmaceutical companies, Kennedy has garnered support from those who have engaged with him privately. Senator Bill Cassidy, a physician with extensive vaccine experience, expressed support after multiple meetings with Kennedy.
The perceived risk of repealing childhood vaccine recommendations seems to be a driving factor behind Kennedy's public shift towards moderation. Bourla notes that Trump "doesn't want another health crisis" during his presidency.
Kennedy's confirmation hearings raised eyebrows as he declined to affirm vaccine safety and efficacy despite ample evidence. He also expressed uncertainty about the COVID-19 vaccine's impact on mortality.
Bourla's close relationship with Trump and his upcoming chairmanship of PhRMA position him as a key industry player. He anticipates engaging with the new administration on policy matters, particularly the upcoming Medicare drug pricing negotiations.
Bourla remains unfazed by the targeted drugs in the negotiations due to expiring patents. He views the new administration as potentially favorable for the pharmaceutical sector, contrasting it with the previous administration under Biden.
Anjalee Khemlani, Yahoo Finance's senior health reporter, covers industry updates including pharmaceutical news and health policy analysis.